Figure 6 | Scientific Reports

Figure 6

From: Inhibition of DNMT3B expression in activated hepatic stellate cells overcomes chemoresistance in the tumor microenvironment of hepatocellular carcinoma

Figure 6

The efficacy of chemotherapeutic drugs against HCC was increased by CHIR-99021. (A) MCHS size was examined after treatment with 1 or 2 µM sorafenib with or without 0.5 µM CHIR-99021 for 2 days. Images (upper) were obtained using an Operetta HCS system, and MCHS sizes were calculated using Harmony software. (B) Cleaved-caspase 3, an apoptosis marker, was examined in MCHSs after treatment with 1 or 3 µM sorafenib with or without 0.5 µM CHIR-99021. (C) Tumor volume was measured for 3 weeks (1 week before and 2 weeks after drug administration) in the 10 mpk sorafenib, 15 mpk CHIR-99021, and 10 mpk sorafenib plus 15 mpk CHIR-99021 groups. (D) Liver toxicity was determined by examining mouse blood (AST; upper, ALT; lower) after completing the in vivo experiment. (E) Expression levels of DNMT3B and Cleaved PARP, an apoptosis marker, were calculated in xenografted tumor tissue. β-actin was used as a control.

Back to article page